Standards & Guidelines


Guest Editorial: Is Cardio-oncology Ready for Algorithms?

Cardio-oncology can be defined as a cross-disciplinary, collaborative sub-specialty focused on the prevention, management and mitigation of cardiovascular disease in cancer patients in order to achieve optimal patient outcomes.1 As such, this sub-specialty has been in existence for approximately 40 years, if not in name, then certainly in its goals of clinical practice and lines of scientific inquiry.

European Society of Cardiology guidelines on syncope launched today at EHRA 2018

Barcelona, Spain – 19 March 2018: European Society of Cardiology guidelines on syncope were launched today at EHRA 2018 and published online in the European Heart Journal.1,2

Syncope is a transient loss of consciousness caused by reduced blood flow to the brain. Approximately 50 per cent of people have one syncopal event during their lifetime. The most common type is vasovagal syncope, commonly known as fainting, triggered by fear, seeing blood, or prolonged standing, for example.

Guidelines for the Management of Patients with Aortic Stenosis Undergoing Noncardiac Surgery: Out of Date and Overly Prescriptive

Patients with severe aortic stenosis who require non-cardiac surgery (NCS) present a difficult clinical problem. It is well established that their rate of postoperative cardiovascular complications is increased in comparison with patients without aortic stenosis,1–3 yet their optimal management remains uncertain.

Contemporary Management of Stroke Prevention in Atrial Fibrillation Following the European Society of Cardiology Guidelines

Prevention of ischaemic stroke has long been central to the management of patients with atrial fibrillation (AF), historically relying on the use of vitamin K antagonists (VKAs) or antiplatelet agents depending on the risk of thromboembolism. Difficulties associated with maintaining VKAs in therapeutic range and the perceived risk of bleeding have been highlighted as reasons to withhold oral anticoagulation (OAC) and these issues have partly been addressed by the introduction of non-vitamin K antagonist oral anticoagulants (NOACs).